MDTF 003 (0.03.1P)

• Research type

  Research Study

• Full title

  A Double-Blind Randomised, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ethyl Lauroyl Arginate Hydrochloride (ELAH) Formulation Versus a Matching Placebo Formulation in Terms of Effective Prevention from SARS-CoV-2 and Other Respiratory Viruses, including H1N1 Influenza and Human RSV

• IRAS ID

  316602

• Contact name

  Adam Nawaz

• Contact email

  adam.nawaz@nhs.net

• Sponsor organisation

  Salvacion USA, Inc

• Duration of Study in the UK

  0 years, 5 months, 1 days

• Research summary

  The primary objective of this study is to evaluate the efficacy of Ethyl Lauroyl Arginate Hydrochloride (ELAH) (0.1% concentration) in reducing the incidence of infection from SARS-CoV-2, H1N1 Influenza, Human RSV and other airborne respiratory viruses.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  23/LO/0134

• Date of REC Opinion

  7 Mar 2023

• REC opinion

  Further Information Favourable Opinion